| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 389 | 2024 | 2634 | 34.480 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 108 | 2024 | 529 | 21.270 |
Why?
|
| Piperazines | 275 | 2015 | 2152 | 20.520 |
Why?
|
| Pyrimidines | 326 | 2021 | 3664 | 20.340 |
Why?
|
| Protein Kinase Inhibitors | 276 | 2024 | 4964 | 18.850 |
Why?
|
| Imatinib Mesylate | 304 | 2024 | 1690 | 15.620 |
Why?
|
| Antineoplastic Agents | 380 | 2024 | 14653 | 13.870 |
Why?
|
| Fusion Proteins, bcr-abl | 165 | 2024 | 1143 | 11.990 |
Why?
|
| Leukemia, Myeloid, Acute | 217 | 2024 | 7258 | 11.680 |
Why?
|
| Benzamides | 275 | 2015 | 1882 | 10.920 |
Why?
|
| Aniline Compounds | 36 | 2024 | 206 | 9.310 |
Why?
|
| Protein-Tyrosine Kinases | 127 | 2017 | 1842 | 9.270 |
Why?
|
| Quinolines | 35 | 2024 | 403 | 9.050 |
Why?
|
| Dasatinib | 110 | 2024 | 881 | 8.710 |
Why?
|
| Thiazoles | 84 | 2018 | 725 | 8.260 |
Why?
|
| Nitriles | 47 | 2024 | 944 | 7.910 |
Why?
|
| Cytarabine | 114 | 2023 | 2014 | 6.990 |
Why?
|
| Drug Resistance, Neoplasm | 177 | 2024 | 5421 | 6.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 218 | 2023 | 16610 | 5.510 |
Why?
|
| Myelodysplastic Syndromes | 112 | 2022 | 3148 | 5.490 |
Why?
|
| Phenylurea Compounds | 30 | 2021 | 600 | 5.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 41 | 2021 | 842 | 4.960 |
Why?
|
| Harringtonines | 21 | 2015 | 93 | 4.900 |
Why?
|
| Blast Crisis | 48 | 2021 | 587 | 4.880 |
Why?
|
| Remission Induction | 146 | 2021 | 3645 | 4.410 |
Why?
|
| Aged | 572 | 2024 | 73494 | 4.230 |
Why?
|
| Middle Aged | 641 | 2024 | 90427 | 4.130 |
Why?
|
| Aged, 80 and over | 333 | 2024 | 31060 | 3.940 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 93 | 2021 | 2903 | 3.910 |
Why?
|
| Humans | 1013 | 2024 | 271941 | 3.890 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 20 | 2018 | 114 | 3.860 |
Why?
|
| Treatment Outcome | 371 | 2024 | 33874 | 3.860 |
Why?
|
| Philadelphia Chromosome | 47 | 2023 | 836 | 3.830 |
Why?
|
| Adult | 558 | 2024 | 81889 | 3.690 |
Why?
|
| Leukemia | 45 | 2023 | 1721 | 3.690 |
Why?
|
| Salvage Therapy | 63 | 2019 | 2119 | 3.500 |
Why?
|
| Daunorubicin | 22 | 2023 | 313 | 3.460 |
Why?
|
| Pyridazines | 21 | 2020 | 319 | 3.330 |
Why?
|
| Male | 558 | 2024 | 128995 | 3.200 |
Why?
|
| Mutation | 118 | 2024 | 15941 | 3.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 15 | 2015 | 895 | 3.010 |
Why?
|
| Imidazoles | 24 | 2020 | 1056 | 2.960 |
Why?
|
| Interferon-alpha | 50 | 2013 | 964 | 2.950 |
Why?
|
| Female | 549 | 2024 | 149187 | 2.920 |
Why?
|
| Benzothiazoles | 10 | 2021 | 101 | 2.860 |
Why?
|
| Benzimidazoles | 14 | 2021 | 442 | 2.830 |
Why?
|
| Hematologic Neoplasms | 25 | 2023 | 1950 | 2.700 |
Why?
|
| Leukemia, Myeloid | 46 | 2019 | 994 | 2.680 |
Why?
|
| Primary Myelofibrosis | 42 | 2024 | 915 | 2.650 |
Why?
|
| Azacitidine | 39 | 2023 | 1219 | 2.630 |
Why?
|
| Young Adult | 173 | 2024 | 22127 | 2.560 |
Why?
|
| Survival Rate | 130 | 2023 | 12533 | 2.510 |
Why?
|
| Follow-Up Studies | 127 | 2024 | 15269 | 2.390 |
Why?
|
| Cytogenetic Analysis | 43 | 2019 | 574 | 2.380 |
Why?
|
| Drug Administration Schedule | 88 | 2021 | 3540 | 2.350 |
Why?
|
| Survival Analysis | 131 | 2021 | 9325 | 2.300 |
Why?
|
| Chromosome Aberrations | 41 | 2019 | 2034 | 2.280 |
Why?
|
| Prognosis | 199 | 2021 | 22550 | 2.280 |
Why?
|
| Adolescent | 224 | 2020 | 32687 | 2.270 |
Why?
|
| Enzyme Inhibitors | 41 | 2024 | 1966 | 2.240 |
Why?
|
| Disease-Free Survival | 110 | 2020 | 10259 | 2.230 |
Why?
|
| Leukemia, Promyelocytic, Acute | 19 | 2015 | 439 | 1.990 |
Why?
|
| Anemia | 21 | 2024 | 730 | 1.950 |
Why?
|
| Clinical Trials as Topic | 67 | 2021 | 3853 | 1.900 |
Why?
|
| Antimetabolites, Antineoplastic | 31 | 2018 | 1351 | 1.870 |
Why?
|
| Recurrence | 75 | 2024 | 4887 | 1.830 |
Why?
|
| Tandem Repeat Sequences | 11 | 2019 | 203 | 1.810 |
Why?
|
| Thrombocytopenia | 19 | 2022 | 872 | 1.790 |
Why?
|
| Pyrazoles | 19 | 2024 | 1544 | 1.790 |
Why?
|
| Neoplasms, Second Primary | 16 | 2022 | 1388 | 1.760 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 118 | 1.630 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 53 | 2021 | 6987 | 1.630 |
Why?
|
| Dose-Response Relationship, Drug | 71 | 2020 | 5105 | 1.590 |
Why?
|
| Bone Marrow | 52 | 2019 | 2446 | 1.580 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 9 | 2017 | 121 | 1.550 |
Why?
|
| Idarubicin | 31 | 2019 | 459 | 1.540 |
Why?
|
| Myeloproliferative Disorders | 23 | 2022 | 881 | 1.450 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2024 | 235 | 1.400 |
Why?
|
| Angiogenesis Inhibitors | 13 | 2021 | 1265 | 1.390 |
Why?
|
| Kaplan-Meier Estimate | 49 | 2024 | 6270 | 1.370 |
Why?
|
| Quinolones | 10 | 2010 | 163 | 1.360 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2019 | 10365 | 1.330 |
Why?
|
| Farnesyltranstransferase | 18 | 2010 | 125 | 1.320 |
Why?
|
| Pyridines | 19 | 2024 | 1312 | 1.310 |
Why?
|
| Alkyl and Aryl Transferases | 9 | 2004 | 92 | 1.300 |
Why?
|
| Stem Cell Transplantation | 30 | 2021 | 1423 | 1.300 |
Why?
|
| Febrile Neutropenia | 5 | 2022 | 74 | 1.260 |
Why?
|
| Vidarabine | 29 | 2018 | 1383 | 1.250 |
Why?
|
| Janus Kinase 2 | 28 | 2018 | 754 | 1.250 |
Why?
|
| Treatment Failure | 29 | 2016 | 1432 | 1.230 |
Why?
|
| Hedgehog Proteins | 5 | 2020 | 441 | 1.210 |
Why?
|
| Point Mutation | 16 | 2019 | 793 | 1.170 |
Why?
|
| Niacinamide | 17 | 2024 | 427 | 1.160 |
Why?
|
| Polycythemia Vera | 15 | 2015 | 268 | 1.160 |
Why?
|
| Hypereosinophilic Syndrome | 13 | 2012 | 86 | 1.120 |
Why?
|
| Multiple Myeloma | 5 | 2022 | 2286 | 1.120 |
Why?
|
| Isocitrate Dehydrogenase | 6 | 2024 | 520 | 1.080 |
Why?
|
| Aminoglycosides | 18 | 2018 | 235 | 1.080 |
Why?
|
| Hematologic Diseases | 9 | 2018 | 255 | 1.080 |
Why?
|
| Randomized Controlled Trials as Topic | 22 | 2022 | 2679 | 1.070 |
Why?
|
| Neoplasm, Residual | 23 | 2016 | 1741 | 1.070 |
Why?
|
| Cytosine | 11 | 2009 | 157 | 1.060 |
Why?
|
| Time Factors | 66 | 2020 | 13130 | 1.050 |
Why?
|
| Genes, abl | 21 | 2019 | 120 | 1.020 |
Why?
|
| Maximum Tolerated Dose | 32 | 2020 | 1323 | 1.000 |
Why?
|
| Clinical Protocols | 2 | 2019 | 485 | 1.000 |
Why?
|
| Pregnancy Outcome | 5 | 2020 | 680 | 0.990 |
Why?
|
| Age Factors | 37 | 2021 | 5521 | 0.980 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 12 | 2013 | 461 | 0.950 |
Why?
|
| Leukemic Infiltration | 5 | 2018 | 73 | 0.940 |
Why?
|
| Drug Approval | 5 | 2024 | 176 | 0.940 |
Why?
|
| Molecular Targeted Therapy | 11 | 2020 | 2400 | 0.940 |
Why?
|
| Hydroxamic Acids | 5 | 2013 | 455 | 0.930 |
Why?
|
| Pleural Effusion | 7 | 2016 | 219 | 0.930 |
Why?
|
| Drug Monitoring | 13 | 2016 | 356 | 0.920 |
Why?
|
| Transplantation, Homologous | 32 | 2019 | 3036 | 0.910 |
Why?
|
| Neoplasm Proteins | 17 | 2020 | 3363 | 0.910 |
Why?
|
| Antibodies, Monoclonal | 39 | 2016 | 4496 | 0.890 |
Why?
|
| Proto-Oncogene Proteins | 17 | 2020 | 2624 | 0.890 |
Why?
|
| Arabinonucleosides | 13 | 2017 | 458 | 0.880 |
Why?
|
| Models, Biological | 7 | 2020 | 3223 | 0.880 |
Why?
|
| Propensity Score | 3 | 2016 | 776 | 0.870 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 27 | 2017 | 2474 | 0.870 |
Why?
|
| Risk Factors | 58 | 2022 | 18047 | 0.860 |
Why?
|
| Vincristine | 37 | 2019 | 1572 | 0.860 |
Why?
|
| Neutropenia | 14 | 2023 | 1001 | 0.860 |
Why?
|
| Benzenesulfonates | 8 | 2012 | 196 | 0.850 |
Why?
|
| Dioxolanes | 10 | 2007 | 51 | 0.840 |
Why?
|
| Breast Feeding | 1 | 2024 | 245 | 0.840 |
Why?
|
| Disease Progression | 47 | 2021 | 6910 | 0.830 |
Why?
|
| Cyclophosphamide | 46 | 2019 | 3231 | 0.820 |
Why?
|
| Metaphase | 5 | 2017 | 124 | 0.800 |
Why?
|
| Cell Transformation, Neoplastic | 12 | 2018 | 2472 | 0.780 |
Why?
|
| Interleukin-11 | 6 | 2008 | 38 | 0.780 |
Why?
|
| Acute Disease | 49 | 2022 | 2514 | 0.780 |
Why?
|
| Thalidomide | 13 | 2014 | 595 | 0.780 |
Why?
|
| Retrospective Studies | 92 | 2021 | 39800 | 0.780 |
Why?
|
| Dexamethasone | 35 | 2021 | 1497 | 0.770 |
Why?
|
| Chromosomes, Human | 4 | 2017 | 290 | 0.770 |
Why?
|
| Tretinoin | 16 | 2015 | 621 | 0.760 |
Why?
|
| Burkitt Lymphoma | 6 | 2017 | 350 | 0.760 |
Why?
|
| Glycine | 2 | 2013 | 319 | 0.750 |
Why?
|
| Translocation, Genetic | 20 | 2020 | 1288 | 0.740 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2020 | 506 | 0.740 |
Why?
|
| Pteridines | 1 | 2020 | 35 | 0.730 |
Why?
|
| Thrombocythemia, Essential | 10 | 2015 | 179 | 0.730 |
Why?
|
| Health Status Disparities | 1 | 2023 | 320 | 0.720 |
Why?
|
| Multivariate Analysis | 37 | 2017 | 4352 | 0.710 |
Why?
|
| Mastocytosis, Systemic | 10 | 2018 | 119 | 0.690 |
Why?
|
| Adenine Nucleotides | 11 | 2017 | 365 | 0.690 |
Why?
|
| Hematinics | 2 | 2011 | 109 | 0.690 |
Why?
|
| Administration, Oral | 23 | 2020 | 1620 | 0.690 |
Why?
|
| Pyrazines | 4 | 2019 | 513 | 0.680 |
Why?
|
| Drug Substitution | 2 | 2018 | 86 | 0.680 |
Why?
|
| Signal Transduction | 27 | 2020 | 12223 | 0.680 |
Why?
|
| Arsenicals | 10 | 2015 | 204 | 0.660 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 7 | 2016 | 629 | 0.660 |
Why?
|
| Piperidines | 9 | 2019 | 1091 | 0.660 |
Why?
|
| Oxides | 9 | 2015 | 212 | 0.660 |
Why?
|
| DNA Mutational Analysis | 19 | 2015 | 2365 | 0.650 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2024 | 624 | 0.640 |
Why?
|
| Lymphoma | 7 | 2015 | 1514 | 0.640 |
Why?
|
| Kidney Diseases | 2 | 2017 | 732 | 0.630 |
Why?
|
| Health Education | 1 | 2020 | 304 | 0.630 |
Why?
|
| Infusions, Intravenous | 26 | 2021 | 1441 | 0.630 |
Why?
|
| In Situ Hybridization, Fluorescence | 19 | 2023 | 2317 | 0.620 |
Why?
|
| Polyethylene Glycols | 11 | 2017 | 642 | 0.620 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 1322 | 0.610 |
Why?
|
| Heart Diseases | 4 | 2021 | 739 | 0.610 |
Why?
|
| Gene Expression Regulation, Leukemic | 11 | 2018 | 582 | 0.600 |
Why?
|
| Apoptosis | 34 | 2016 | 7837 | 0.600 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 3 | 2009 | 109 | 0.600 |
Why?
|
| Doxorubicin | 31 | 2019 | 3131 | 0.600 |
Why?
|
| Combined Modality Therapy | 32 | 2020 | 9044 | 0.600 |
Why?
|
| Retreatment | 9 | 2018 | 447 | 0.590 |
Why?
|
| Boronic Acids | 3 | 2011 | 355 | 0.590 |
Why?
|
| Erythropoietin | 4 | 2011 | 219 | 0.590 |
Why?
|
| Europe | 9 | 2018 | 659 | 0.590 |
Why?
|
| Mutation, Missense | 8 | 2019 | 1197 | 0.570 |
Why?
|
| Oncogene Proteins, Fusion | 12 | 2020 | 802 | 0.560 |
Why?
|
| Prospective Studies | 28 | 2020 | 13402 | 0.550 |
Why?
|
| Karyotyping | 20 | 2015 | 1064 | 0.550 |
Why?
|
| Nausea | 10 | 2023 | 540 | 0.550 |
Why?
|
| United States | 24 | 2024 | 16053 | 0.550 |
Why?
|
| Cause of Death | 4 | 2020 | 787 | 0.540 |
Why?
|
| Clinical Trials, Phase II as Topic | 11 | 2020 | 686 | 0.540 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2020 | 40 | 0.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 27 | 2021 | 3393 | 0.540 |
Why?
|
| Cancer Vaccines | 6 | 2009 | 754 | 0.540 |
Why?
|
| Staurosporine | 8 | 2019 | 149 | 0.540 |
Why?
|
| Vascular Diseases | 2 | 2016 | 243 | 0.530 |
Why?
|
| Health Care Costs | 4 | 2014 | 699 | 0.530 |
Why?
|
| Immunotoxins | 5 | 2012 | 120 | 0.530 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 864 | 0.530 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 430 | 0.530 |
Why?
|
| Drug Therapy, Combination | 14 | 2018 | 2366 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2017 | 296 | 0.520 |
Why?
|
| Consolidation Chemotherapy | 6 | 2018 | 154 | 0.510 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2014 | 426 | 0.510 |
Why?
|
| Thrombosis | 6 | 2019 | 755 | 0.510 |
Why?
|
| Gene Expression | 5 | 2020 | 3689 | 0.500 |
Why?
|
| Sarcoma, Myeloid | 2 | 2013 | 94 | 0.490 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 161 | 0.490 |
Why?
|
| Cancer Survivors | 1 | 2022 | 744 | 0.490 |
Why?
|
| Anemia, Refractory | 2 | 2013 | 40 | 0.480 |
Why?
|
| Methotrexate | 16 | 2017 | 1032 | 0.480 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2015 | 114 | 0.480 |
Why?
|
| Chin | 1 | 2014 | 11 | 0.480 |
Why?
|
| Cohort Studies | 30 | 2020 | 9494 | 0.480 |
Why?
|
| Benzoates | 1 | 2015 | 130 | 0.470 |
Why?
|
| Surveys and Questionnaires | 8 | 2020 | 5929 | 0.470 |
Why?
|
| Peripheral Nervous System | 1 | 2014 | 51 | 0.470 |
Why?
|
| Drug Evaluation, Preclinical | 11 | 2012 | 503 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-abl | 5 | 2009 | 83 | 0.460 |
Why?
|
| Cytogenetics | 7 | 2013 | 152 | 0.460 |
Why?
|
| Blepharoplasty | 1 | 2014 | 25 | 0.450 |
Why?
|
| Incidence | 19 | 2021 | 5861 | 0.450 |
Why?
|
| Purpura | 1 | 2014 | 35 | 0.450 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1335 | 0.450 |
Why?
|
| Disease Management | 6 | 2021 | 1111 | 0.440 |
Why?
|
| Eyelid Diseases | 1 | 2014 | 74 | 0.440 |
Why?
|
| Neoplasm Staging | 23 | 2018 | 13993 | 0.440 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 2129 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2020 | 335 | 0.440 |
Why?
|
| Biomarkers, Tumor | 25 | 2020 | 10750 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-kit | 12 | 2013 | 490 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2015 | 413 | 0.440 |
Why?
|
| Animals | 56 | 2021 | 62823 | 0.440 |
Why?
|
| Maintenance Chemotherapy | 4 | 2021 | 224 | 0.440 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2022 | 499 | 0.440 |
Why?
|
| Clone Cells | 10 | 2011 | 589 | 0.440 |
Why?
|
| Hematopoiesis | 4 | 2013 | 608 | 0.430 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2013 | 32 | 0.430 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 24 | 2015 | 3651 | 0.430 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2013 | 71 | 0.430 |
Why?
|
| Induction Chemotherapy | 10 | 2019 | 671 | 0.430 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2020 | 2357 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 1232 | 0.420 |
Why?
|
| Liposomes | 13 | 2014 | 710 | 0.420 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2012 | 22 | 0.420 |
Why?
|
| Neoplastic Stem Cells | 10 | 2014 | 1469 | 0.420 |
Why?
|
| Chromosome Deletion | 7 | 2013 | 1055 | 0.420 |
Why?
|
| Stem Cell Factor | 3 | 2013 | 88 | 0.420 |
Why?
|
| Pilot Projects | 18 | 2014 | 2866 | 0.410 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 1340 | 0.410 |
Why?
|
| Recombinant Proteins | 18 | 2013 | 3072 | 0.410 |
Why?
|
| Edema | 1 | 2014 | 264 | 0.400 |
Why?
|
| Hydroxyurea | 7 | 2020 | 224 | 0.400 |
Why?
|
| Multicenter Studies as Topic | 5 | 2022 | 566 | 0.400 |
Why?
|
| Protein Biosynthesis | 3 | 2014 | 1035 | 0.390 |
Why?
|
| Interferon Type I | 6 | 2006 | 283 | 0.390 |
Why?
|
| Antibodies, Neoplasm | 7 | 2010 | 275 | 0.390 |
Why?
|
| Proportional Hazards Models | 24 | 2021 | 5118 | 0.390 |
Why?
|
| Hypertension | 2 | 2021 | 1624 | 0.390 |
Why?
|
| Cardiovascular System | 1 | 2013 | 151 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 19 | 2014 | 3512 | 0.380 |
Why?
|
| Immunosuppressive Agents | 6 | 2011 | 1442 | 0.380 |
Why?
|
| Platelet Count | 16 | 2014 | 491 | 0.380 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2018 | 319 | 0.370 |
Why?
|
| Quality of Life | 9 | 2022 | 4749 | 0.370 |
Why?
|
| Sulfonamides | 11 | 2021 | 1919 | 0.370 |
Why?
|
| Risk Assessment | 18 | 2021 | 6883 | 0.370 |
Why?
|
| Splenomegaly | 8 | 2015 | 173 | 0.370 |
Why?
|
| Down Syndrome | 1 | 2013 | 227 | 0.360 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2011 | 257 | 0.360 |
Why?
|
| Severity of Illness Index | 12 | 2015 | 4399 | 0.360 |
Why?
|
| src-Family Kinases | 6 | 2011 | 487 | 0.360 |
Why?
|
| Camptothecin | 5 | 2006 | 538 | 0.360 |
Why?
|
| Cyclosporine | 7 | 2009 | 296 | 0.360 |
Why?
|
| Urate Oxidase | 1 | 2010 | 43 | 0.360 |
Why?
|
| Histone Deacetylase Inhibitors | 9 | 2014 | 621 | 0.360 |
Why?
|
| Antigens, CD34 | 8 | 2013 | 643 | 0.360 |
Why?
|
| Transplantation Conditioning | 9 | 2014 | 2359 | 0.360 |
Why?
|
| Central Nervous System Neoplasms | 6 | 2008 | 550 | 0.360 |
Why?
|
| Oligonucleotides | 1 | 2011 | 245 | 0.350 |
Why?
|
| Exanthema | 4 | 2022 | 210 | 0.350 |
Why?
|
| Congresses as Topic | 2 | 2018 | 296 | 0.350 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2020 | 770 | 0.350 |
Why?
|
| Hyperuricemia | 1 | 2010 | 49 | 0.350 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2014 | 744 | 0.350 |
Why?
|
| Cost of Illness | 1 | 2013 | 505 | 0.350 |
Why?
|
| Probability | 10 | 2012 | 887 | 0.340 |
Why?
|
| Gene Duplication | 4 | 2018 | 433 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 14 | 2014 | 879 | 0.340 |
Why?
|
| Uric Acid | 1 | 2010 | 121 | 0.340 |
Why?
|
| Injections, Subcutaneous | 8 | 2013 | 344 | 0.340 |
Why?
|
| Topoisomerase I Inhibitors | 3 | 2006 | 73 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 5 | 6 | 2013 | 274 | 0.340 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 211 | 0.340 |
Why?
|
| Allopurinol | 1 | 2010 | 87 | 0.340 |
Why?
|
| Cardiovascular Diseases | 7 | 2019 | 2307 | 0.340 |
Why?
|
| Immunophenotyping | 10 | 2018 | 1732 | 0.340 |
Why?
|
| Health Care Rationing | 1 | 2010 | 79 | 0.330 |
Why?
|
| Benzodiazepines | 3 | 2005 | 174 | 0.330 |
Why?
|
| DNA Methylation | 17 | 2021 | 2761 | 0.330 |
Why?
|
| Valproic Acid | 4 | 2014 | 276 | 0.320 |
Why?
|
| Nuclear Proteins | 10 | 2014 | 3472 | 0.320 |
Why?
|
| Blood Platelets | 1 | 2013 | 684 | 0.320 |
Why?
|
| Vomiting | 9 | 2023 | 361 | 0.320 |
Why?
|
| Vaccines, Subunit | 1 | 2009 | 127 | 0.320 |
Why?
|
| Biomarkers | 13 | 2020 | 5114 | 0.320 |
Why?
|
| Antigens, CD | 10 | 2013 | 1436 | 0.320 |
Why?
|
| Core Binding Factors | 4 | 2014 | 113 | 0.320 |
Why?
|
| Thrombocytosis | 3 | 2023 | 142 | 0.320 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 173 | 0.310 |
Why?
|
| United States Food and Drug Administration | 4 | 2023 | 329 | 0.310 |
Why?
|
| Janus Kinase 1 | 4 | 2014 | 125 | 0.310 |
Why?
|
| Rituximab | 16 | 2017 | 1588 | 0.300 |
Why?
|
| Bone Marrow Cells | 11 | 2020 | 983 | 0.300 |
Why?
|
| Liver Diseases | 3 | 2012 | 605 | 0.300 |
Why?
|
| Ki-1 Antigen | 3 | 2013 | 186 | 0.300 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 318 | 0.300 |
Why?
|
| Prednisone | 10 | 2017 | 1036 | 0.290 |
Why?
|
| Patient Selection | 5 | 2021 | 2043 | 0.290 |
Why?
|
| Pregnancy | 7 | 2024 | 8100 | 0.290 |
Why?
|
| Safety | 8 | 2018 | 465 | 0.290 |
Why?
|
| Diarrhea | 10 | 2023 | 730 | 0.290 |
Why?
|
| Leukocyte Count | 13 | 2021 | 738 | 0.290 |
Why?
|
| Flow Cytometry | 16 | 2016 | 3078 | 0.290 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2009 | 157 | 0.290 |
Why?
|
| Patient Preference | 1 | 2009 | 225 | 0.280 |
Why?
|
| HLA Antigens | 5 | 2014 | 588 | 0.280 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2014 | 320 | 0.280 |
Why?
|
| Genes, p53 | 1 | 2011 | 1146 | 0.280 |
Why?
|
| Genes, ras | 5 | 2015 | 681 | 0.280 |
Why?
|
| Mast Cells | 4 | 2013 | 231 | 0.280 |
Why?
|
| Cranial Irradiation | 4 | 2010 | 322 | 0.280 |
Why?
|
| Medical Oncology | 4 | 2015 | 1463 | 0.280 |
Why?
|
| Carbazoles | 3 | 2014 | 92 | 0.270 |
Why?
|
| Receptors, CXCR4 | 3 | 2020 | 281 | 0.270 |
Why?
|
| Central Nervous System | 3 | 2010 | 457 | 0.270 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2006 | 99 | 0.270 |
Why?
|
| Topotecan | 10 | 2006 | 248 | 0.270 |
Why?
|
| Structure-Activity Relationship | 7 | 2012 | 1005 | 0.260 |
Why?
|
| Phosphoramide Mustards | 2 | 2016 | 37 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 4 | 2016 | 45 | 0.260 |
Why?
|
| Treatment Refusal | 1 | 2007 | 128 | 0.260 |
Why?
|
| Drug Delivery Systems | 6 | 2010 | 664 | 0.260 |
Why?
|
| Drug Screening Assays, Antitumor | 8 | 2015 | 569 | 0.260 |
Why?
|
| Weight Gain | 1 | 2009 | 474 | 0.260 |
Why?
|
| Eosinophilia | 2 | 2023 | 188 | 0.260 |
Why?
|
| Itraconazole | 4 | 2009 | 81 | 0.260 |
Why?
|
| Teratogens | 1 | 2006 | 92 | 0.260 |
Why?
|
| Kidney | 2 | 2015 | 2267 | 0.260 |
Why?
|
| Amino Acid Substitution | 8 | 2015 | 661 | 0.260 |
Why?
|
| Transcription Factors | 5 | 2016 | 5506 | 0.250 |
Why?
|
| Patient Compliance | 1 | 2010 | 681 | 0.250 |
Why?
|
| Nitroimidazoles | 2 | 2016 | 107 | 0.250 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 323 | 0.250 |
Why?
|
| Analysis of Variance | 7 | 2015 | 2337 | 0.250 |
Why?
|
| Risk | 12 | 2021 | 1950 | 0.250 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2021 | 996 | 0.250 |
Why?
|
| Peptides | 4 | 2020 | 1529 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2012 | 609 | 0.250 |
Why?
|
| Patient Outcome Assessment | 2 | 2017 | 247 | 0.240 |
Why?
|
| Protein Structure, Tertiary | 6 | 2012 | 1501 | 0.240 |
Why?
|
| Blood Transfusion | 3 | 2020 | 583 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2015 | 325 | 0.240 |
Why?
|
| Hepatic Veno-Occlusive Disease | 4 | 2020 | 135 | 0.240 |
Why?
|
| Research Design | 4 | 2019 | 1581 | 0.230 |
Why?
|
| Cell Survival | 16 | 2016 | 3074 | 0.230 |
Why?
|
| Child | 26 | 2019 | 30499 | 0.230 |
Why?
|
| Phosphorylation | 19 | 2014 | 4984 | 0.230 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 6 | 2003 | 88 | 0.230 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2016 | 64 | 0.230 |
Why?
|
| Heart Failure | 3 | 2016 | 2500 | 0.230 |
Why?
|
| Lymphocyte Activation | 2 | 2006 | 1728 | 0.230 |
Why?
|
| Latin America | 2 | 2016 | 126 | 0.230 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 2 | 2019 | 13 | 0.230 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 2053 | 0.230 |
Why?
|
| beta 2-Microglobulin | 5 | 2009 | 189 | 0.230 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.230 |
Why?
|
| Hypoxia | 3 | 2016 | 477 | 0.220 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 5996 | 0.220 |
Why?
|
| Endothelial Growth Factors | 6 | 2003 | 234 | 0.220 |
Why?
|
| ras Proteins | 4 | 2013 | 802 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2004 | 370 | 0.220 |
Why?
|
| Lymphokines | 6 | 2003 | 317 | 0.220 |
Why?
|
| Neoplasms | 10 | 2015 | 15928 | 0.220 |
Why?
|
| Injections | 2 | 2014 | 286 | 0.220 |
Why?
|
| Recovery of Function | 1 | 2006 | 691 | 0.220 |
Why?
|
| Ondansetron | 2 | 2015 | 39 | 0.220 |
Why?
|
| Fatigue | 8 | 2018 | 1280 | 0.220 |
Why?
|
| Leukocytosis | 3 | 2023 | 115 | 0.210 |
Why?
|
| Pyrrolidines | 2 | 2015 | 114 | 0.210 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 606 | 0.210 |
Why?
|
| Erythema | 2 | 2003 | 48 | 0.210 |
Why?
|
| Leukemia, B-Cell | 3 | 2017 | 114 | 0.210 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2008 | 130 | 0.210 |
Why?
|
| Drug Costs | 3 | 2015 | 140 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2013 | 1547 | 0.210 |
Why?
|
| Income | 1 | 2023 | 232 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2013 | 1373 | 0.200 |
Why?
|
| Leukapheresis | 2 | 2014 | 166 | 0.200 |
Why?
|
| Blood Cell Count | 6 | 2009 | 234 | 0.200 |
Why?
|
| Paresthesia | 1 | 2002 | 33 | 0.200 |
Why?
|
| Spinal Cord | 2 | 2015 | 724 | 0.200 |
Why?
|
| Antimetabolites | 2 | 2021 | 77 | 0.200 |
Why?
|
| B-Lymphocytes | 3 | 2016 | 1429 | 0.200 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 876 | 0.200 |
Why?
|
| Basophils | 3 | 2011 | 45 | 0.200 |
Why?
|
| Medical Records | 4 | 2014 | 447 | 0.200 |
Why?
|
| Bone and Bones | 3 | 2016 | 613 | 0.200 |
Why?
|
| Chromosome Banding | 3 | 2014 | 280 | 0.200 |
Why?
|
| Interferons | 3 | 2012 | 301 | 0.200 |
Why?
|
| Biphenyl Compounds | 4 | 2016 | 192 | 0.200 |
Why?
|
| Siblings | 6 | 2014 | 312 | 0.200 |
Why?
|
| Food Supply | 1 | 2022 | 101 | 0.200 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 595 | 0.190 |
Why?
|
| Karyotype | 6 | 2020 | 237 | 0.190 |
Why?
|
| Symptom Assessment | 2 | 2021 | 274 | 0.190 |
Why?
|
| Child, Preschool | 18 | 2019 | 17006 | 0.190 |
Why?
|
| Foot | 1 | 2002 | 108 | 0.190 |
Why?
|
| Deoxycytidine | 2 | 2004 | 1378 | 0.190 |
Why?
|
| Calreticulin | 3 | 2018 | 87 | 0.190 |
Why?
|
| Community Mental Health Centers | 1 | 2020 | 9 | 0.190 |
Why?
|
| Hemoglobins | 5 | 2014 | 485 | 0.190 |
Why?
|
| Asparaginase | 7 | 2019 | 186 | 0.190 |
Why?
|
| Cell Line, Tumor | 22 | 2016 | 14881 | 0.190 |
Why?
|
| Hand | 1 | 2002 | 176 | 0.190 |
Why?
|
| Splenectomy | 4 | 2013 | 168 | 0.190 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2021 | 32 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 967 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 157 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2017 | 1068 | 0.180 |
Why?
|
| Fatal Outcome | 5 | 2013 | 835 | 0.180 |
Why?
|
| Karnofsky Performance Status | 1 | 2021 | 174 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 12012 | 0.180 |
Why?
|
| Asia | 2 | 2021 | 155 | 0.180 |
Why?
|
| Genomics | 4 | 2022 | 2830 | 0.180 |
Why?
|
| Peptides, Cyclic | 2 | 2015 | 139 | 0.180 |
Why?
|
| Fever | 5 | 2016 | 516 | 0.180 |
Why?
|
| Receptors, Immunologic | 2 | 2018 | 319 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2016 | 685 | 0.180 |
Why?
|
| Drug Resistance, Multiple | 4 | 2013 | 221 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 65 | 0.180 |
Why?
|
| Poverty | 1 | 2023 | 478 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 309 | 0.170 |
Why?
|
| RNA, Neoplasm | 6 | 2013 | 810 | 0.170 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2014 | 155 | 0.170 |
Why?
|
| Feeding and Eating Disorders | 1 | 2020 | 91 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 13 | 2016 | 5804 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 4 | 2003 | 147 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4889 | 0.170 |
Why?
|
| Mitoxantrone | 2 | 2014 | 227 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 1263 | 0.170 |
Why?
|
| Antigens, Neoplasm | 5 | 2008 | 1590 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2014 | 668 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2021 | 1207 | 0.170 |
Why?
|
| Chronic Disease | 9 | 2018 | 1853 | 0.170 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 38 | 0.170 |
Why?
|
| Biopsy | 9 | 2018 | 3544 | 0.170 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2013 | 404 | 0.170 |
Why?
|
| Thiazolidines | 2 | 2016 | 15 | 0.170 |
Why?
|
| Terminal Care | 2 | 2015 | 465 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2014 | 5690 | 0.160 |
Why?
|
| Naphthyridines | 2 | 2018 | 43 | 0.160 |
Why?
|
| Leukemia, Prolymphocytic | 3 | 2009 | 54 | 0.160 |
Why?
|
| Physical Examination | 1 | 2021 | 304 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 9 | 2007 | 1592 | 0.160 |
Why?
|
| Antifungal Agents | 4 | 2009 | 877 | 0.160 |
Why?
|
| Antineoplastic Protocols | 2 | 2016 | 36 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 293 | 0.160 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 3 | 2017 | 59 | 0.160 |
Why?
|
| Pleural Diseases | 1 | 2019 | 58 | 0.160 |
Why?
|
| Withholding Treatment | 4 | 2013 | 155 | 0.160 |
Why?
|
| Graft vs Host Disease | 5 | 2019 | 2804 | 0.160 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 203 | 0.160 |
Why?
|
| Etoposide | 4 | 2017 | 905 | 0.160 |
Why?
|
| Blotting, Western | 15 | 2013 | 3646 | 0.160 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 100 | 0.160 |
Why?
|
| Comorbidity | 3 | 2021 | 2439 | 0.160 |
Why?
|
| Survivors | 2 | 2022 | 1025 | 0.160 |
Why?
|
| Amsacrine | 2 | 2014 | 63 | 0.160 |
Why?
|
| Age of Onset | 4 | 2011 | 852 | 0.150 |
Why?
|
| RNA, Messenger | 15 | 2013 | 6489 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factors | 6 | 2003 | 249 | 0.150 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 50 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 111 | 0.150 |
Why?
|
| Epigenesis, Genetic | 6 | 2018 | 1439 | 0.150 |
Why?
|
| Creatinine | 2 | 2017 | 546 | 0.150 |
Why?
|
| Chromosome Disorders | 3 | 1999 | 425 | 0.150 |
Why?
|
| Odds Ratio | 5 | 2015 | 2335 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 545 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2012 | 257 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 1296 | 0.150 |
Why?
|
| Cladribine | 4 | 2014 | 253 | 0.150 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 4998 | 0.150 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 96 | 0.150 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2018 | 160 | 0.150 |
Why?
|
| Sensitivity and Specificity | 8 | 2013 | 5195 | 0.150 |
Why?
|
| Bortezomib | 3 | 2011 | 542 | 0.150 |
Why?
|
| Opportunistic Infections | 2 | 2013 | 237 | 0.150 |
Why?
|
| Cell Proliferation | 16 | 2016 | 7302 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2017 | 183 | 0.150 |
Why?
|
| Prodrugs | 2 | 2016 | 226 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2008 | 640 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2015 | 2287 | 0.140 |
Why?
|
| Unrelated Donors | 3 | 2013 | 321 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2015 | 382 | 0.140 |
Why?
|
| Immunotherapy | 7 | 2017 | 3546 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 206 | 0.140 |
Why?
|
| Mycoses | 3 | 2009 | 396 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Pentostatin | 1 | 1997 | 121 | 0.140 |
Why?
|
| Canada | 1 | 2018 | 441 | 0.140 |
Why?
|
| Myeloablative Agonists | 3 | 2013 | 386 | 0.140 |
Why?
|
| Case-Control Studies | 11 | 2018 | 6236 | 0.140 |
Why?
|
| Protein Binding | 7 | 2014 | 3528 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.140 |
Why?
|
| Proteasome Inhibitors | 2 | 2011 | 234 | 0.140 |
Why?
|
| Drug Evaluation | 3 | 2013 | 435 | 0.140 |
Why?
|
| Caspase 3 | 6 | 2007 | 481 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 1039 | 0.140 |
Why?
|
| Mucositis | 2 | 2015 | 150 | 0.140 |
Why?
|
| Logistic Models | 7 | 2019 | 3469 | 0.140 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 2 | 2007 | 57 | 0.140 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2017 | 120 | 0.140 |
Why?
|
| Anthracyclines | 4 | 2010 | 339 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 3 | 2018 | 617 | 0.140 |
Why?
|
| Obesity | 1 | 2009 | 2958 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2014 | 1860 | 0.140 |
Why?
|
| Alkylating Agents | 3 | 2005 | 82 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 10 | 2003 | 3176 | 0.130 |
Why?
|
| Furans | 2 | 2014 | 103 | 0.130 |
Why?
|
| Phenotype | 7 | 2018 | 6516 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 4891 | 0.130 |
Why?
|
| Pneumonia | 4 | 2021 | 798 | 0.130 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 124 | 0.130 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2013 | 151 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2015 | 9101 | 0.130 |
Why?
|
| Cell Cycle | 8 | 2009 | 2150 | 0.130 |
Why?
|
| Whole-Body Irradiation | 2 | 2013 | 324 | 0.130 |
Why?
|
| Adenine | 1 | 2019 | 669 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 229 | 0.130 |
Why?
|
| Lymphocytosis | 1 | 2016 | 58 | 0.130 |
Why?
|
| Glycoproteins | 5 | 2006 | 792 | 0.130 |
Why?
|
| Headache | 1 | 2016 | 175 | 0.130 |
Why?
|
| Drug Tolerance | 3 | 2010 | 123 | 0.130 |
Why?
|
| Algorithms | 7 | 2012 | 3924 | 0.130 |
Why?
|
| Prescription Fees | 1 | 2015 | 17 | 0.130 |
Why?
|
| Anemia, Aplastic | 3 | 2009 | 233 | 0.130 |
Why?
|
| Monitoring, Physiologic | 2 | 2010 | 536 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 228 | 0.130 |
Why?
|
| Protein Phosphatase 2 | 2 | 2013 | 91 | 0.130 |
Why?
|
| Receptors, Interleukin-11 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Injections, Spinal | 4 | 2015 | 275 | 0.130 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2009 | 599 | 0.130 |
Why?
|
| Farnesol | 1 | 2015 | 17 | 0.130 |
Why?
|
| Thiosemicarbazones | 2 | 2006 | 24 | 0.120 |
Why?
|
| Patient Advocacy | 1 | 2015 | 89 | 0.120 |
Why?
|
| Chromosome Inversion | 4 | 2012 | 197 | 0.120 |
Why?
|
| Veratrum Alkaloids | 1 | 2015 | 35 | 0.120 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 140 | 0.120 |
Why?
|
| Random Allocation | 1 | 2016 | 746 | 0.120 |
Why?
|
| Necrosis | 2 | 2015 | 604 | 0.120 |
Why?
|
| Salicylates | 1 | 2015 | 73 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2013 | 911 | 0.120 |
Why?
|
| raf Kinases | 1 | 2015 | 80 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2020 | 271 | 0.120 |
Why?
|
| Erythrocyte Indices | 1 | 2014 | 24 | 0.120 |
Why?
|
| Leukemia, Experimental | 2 | 2008 | 83 | 0.120 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2014 | 27 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 1997 | 482 | 0.120 |
Why?
|
| Bone Marrow Examination | 3 | 2016 | 151 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2024 | 1668 | 0.120 |
Why?
|
| Models, Theoretical | 3 | 2008 | 809 | 0.120 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2014 | 25 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 3417 | 0.120 |
Why?
|
| Trisomy | 3 | 2014 | 240 | 0.120 |
Why?
|
| STAT5 Transcription Factor | 4 | 2008 | 227 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2012 | 1737 | 0.120 |
Why?
|
| Spinal Cord Diseases | 1 | 2015 | 90 | 0.120 |
Why?
|
| Mice | 21 | 2021 | 36054 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2014 | 67 | 0.120 |
Why?
|
| Ecchymosis | 1 | 2014 | 17 | 0.120 |
Why?
|
| Alemtuzumab | 7 | 2012 | 208 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2019 | 234 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 237 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 128 | 0.120 |
Why?
|
| Specialization | 1 | 2015 | 129 | 0.120 |
Why?
|
| Pancreatitis | 2 | 2016 | 293 | 0.110 |
Why?
|
| Hyperpigmentation | 1 | 2014 | 35 | 0.110 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 29 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2014 | 142 | 0.110 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.110 |
Why?
|
| Mice, SCID | 7 | 2015 | 1851 | 0.110 |
Why?
|
| CTLA-4 Antigen | 2 | 2018 | 681 | 0.110 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 183 | 0.110 |
Why?
|
| Infusions, Subcutaneous | 1 | 2013 | 14 | 0.110 |
Why?
|
| Time | 3 | 2020 | 186 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 1143 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 300 | 0.110 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 5187 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2009 | 673 | 0.110 |
Why?
|
| Proteome | 2 | 2016 | 573 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 269 | 0.110 |
Why?
|
| Proteomics | 3 | 2016 | 1437 | 0.110 |
Why?
|
| Self Administration | 1 | 2013 | 58 | 0.110 |
Why?
|
| Sex Factors | 3 | 2015 | 2206 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 5 | 2012 | 2429 | 0.110 |
Why?
|
| Proline | 1 | 2013 | 127 | 0.110 |
Why?
|
| Phenanthrenes | 2 | 2011 | 43 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 845 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2014 | 340 | 0.110 |
Why?
|
| Morpholines | 1 | 2015 | 296 | 0.110 |
Why?
|
| Gene Deletion | 5 | 2017 | 1487 | 0.110 |
Why?
|
| Janus Kinases | 2 | 2012 | 175 | 0.110 |
Why?
|
| Hydrazines | 2 | 2005 | 214 | 0.110 |
Why?
|
| Tryptases | 1 | 2013 | 48 | 0.110 |
Why?
|
| CD11a Antigen | 1 | 2012 | 16 | 0.110 |
Why?
|
| China | 1 | 2014 | 645 | 0.110 |
Why?
|
| Membrane Proteins | 4 | 2014 | 2975 | 0.110 |
Why?
|
| World Health Organization | 2 | 2022 | 328 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2014 | 185 | 0.110 |
Why?
|
| Amylases | 1 | 2012 | 67 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 138 | 0.110 |
Why?
|
| Blood Donors | 1 | 2013 | 173 | 0.110 |
Why?
|
| Diterpenes | 2 | 2011 | 117 | 0.100 |
Why?
|
| CD18 Antigens | 1 | 2012 | 87 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2010 | 1904 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 235 | 0.100 |
Why?
|
| Hydralazine | 1 | 2012 | 13 | 0.100 |
Why?
|
| Cost Savings | 1 | 2013 | 123 | 0.100 |
Why?
|
| Spleen | 5 | 2015 | 732 | 0.100 |
Why?
|
| Propylene Glycols | 2 | 2013 | 39 | 0.100 |
Why?
|
| Sphingosine | 2 | 2013 | 59 | 0.100 |
Why?
|
| Drug Resistance | 2 | 2011 | 615 | 0.100 |
Why?
|
| DNA-Binding Proteins | 7 | 2015 | 5067 | 0.100 |
Why?
|
| Drug Interactions | 3 | 2009 | 584 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2018 | 1327 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2014 | 719 | 0.100 |
Why?
|
| Urea | 1 | 2013 | 306 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 126 | 0.100 |
Why?
|
| Reproducibility of Results | 6 | 2013 | 6210 | 0.100 |
Why?
|
| Lipase | 1 | 2012 | 124 | 0.100 |
Why?
|
| DNA Modification Methylases | 6 | 2012 | 176 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 1091 | 0.100 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 74 | 0.100 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 111 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 5 | 2017 | 5213 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 6 | 2006 | 1599 | 0.100 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2012 | 71 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2013 | 196 | 0.100 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2009 | 123 | 0.100 |
Why?
|
| Pyrroles | 2 | 2008 | 592 | 0.100 |
Why?
|
| Epoetin Alfa | 1 | 2011 | 27 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2009 | 107 | 0.100 |
Why?
|
| SEER Program | 2 | 2012 | 1047 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2009 | 243 | 0.100 |
Why?
|
| Nomograms | 3 | 2011 | 313 | 0.100 |
Why?
|
| Health Surveys | 2 | 2010 | 402 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2009 | 148 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2013 | 520 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 202 | 0.100 |
Why?
|
| Stromal Cells | 2 | 2013 | 835 | 0.100 |
Why?
|
| Membrane Microdomains | 1 | 2011 | 82 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 1575 | 0.100 |
Why?
|
| Patient Participation | 1 | 2015 | 449 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2085 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2015 | 3929 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2013 | 201 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2014 | 122 | 0.090 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 341 | 0.090 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 50 | 0.090 |
Why?
|
| Mercaptopurine | 4 | 2014 | 131 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 428 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2012 | 422 | 0.090 |
Why?
|
| Models, Molecular | 4 | 2008 | 1756 | 0.090 |
Why?
|
| Infant | 6 | 2019 | 13936 | 0.090 |
Why?
|
| Neuropilin-1 | 1 | 2010 | 41 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 2009 | 233 | 0.090 |
Why?
|
| Feasibility Studies | 6 | 2018 | 2351 | 0.090 |
Why?
|
| Drug Carriers | 5 | 2005 | 336 | 0.090 |
Why?
|
| Erythroid Precursor Cells | 2 | 2008 | 70 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 1409 | 0.090 |
Why?
|
| Molecular Biology | 2 | 2008 | 181 | 0.090 |
Why?
|
| Quinuclidines | 1 | 2010 | 47 | 0.090 |
Why?
|
| Amphotericin B | 2 | 2003 | 304 | 0.090 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 4 | 2003 | 95 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2013 | 1196 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2010 | 63 | 0.090 |
Why?
|
| Isoquinolines | 1 | 2010 | 125 | 0.090 |
Why?
|
| Health Policy | 1 | 2013 | 280 | 0.090 |
Why?
|
| Stereoisomerism | 2 | 2008 | 178 | 0.090 |
Why?
|
| Mutagenesis | 2 | 2009 | 524 | 0.090 |
Why?
|
| Models, Statistical | 2 | 2013 | 1190 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2012 | 550 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 2 | 2012 | 954 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 5 | 2012 | 1146 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 207 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 120 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2010 | 84 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2012 | 475 | 0.090 |
Why?
|
| Antigens, CD20 | 2 | 2008 | 207 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2010 | 51 | 0.090 |
Why?
|
| Mice, Inbred NOD | 4 | 2015 | 910 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 936 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 624 | 0.090 |
Why?
|
| Genes, p16 | 2 | 2000 | 132 | 0.090 |
Why?
|
| Texas | 5 | 2012 | 6435 | 0.090 |
Why?
|
| Telomerase | 2 | 2003 | 543 | 0.090 |
Why?
|
| Antiemetics | 1 | 2010 | 122 | 0.080 |
Why?
|
| Peptide Chain Termination, Translational | 1 | 2009 | 6 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2013 | 1212 | 0.080 |
Why?
|
| Orosomucoid | 1 | 2009 | 13 | 0.080 |
Why?
|
| Spain | 1 | 2009 | 101 | 0.080 |
Why?
|
| Hospitals, Public | 1 | 2009 | 60 | 0.080 |
Why?
|
| Nervous System Diseases | 3 | 2003 | 522 | 0.080 |
Why?
|
| Pericardial Effusion | 1 | 2010 | 126 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2009 | 92 | 0.080 |
Why?
|
| Histocompatibility | 1 | 2009 | 182 | 0.080 |
Why?
|
| Gene Rearrangement | 3 | 2011 | 817 | 0.080 |
Why?
|
| Hemorrhagic Disorders | 1 | 2009 | 52 | 0.080 |
Why?
|
| Oxygen | 1 | 2013 | 800 | 0.080 |
Why?
|
| Blood Platelet Disorders | 1 | 2009 | 35 | 0.080 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2007 | 50 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 296 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2009 | 129 | 0.080 |
Why?
|
| Standard of Care | 1 | 2010 | 276 | 0.080 |
Why?
|
| DNA Mismatch Repair | 1 | 2011 | 284 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2008 | 1483 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 919 | 0.080 |
Why?
|
| Living Donors | 1 | 2009 | 178 | 0.080 |
Why?
|
| Leukemia, Lymphoid | 3 | 2003 | 290 | 0.080 |
Why?
|
| Mycobacterium marinum | 1 | 2008 | 7 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 217 | 0.080 |
Why?
|
| Abortion, Spontaneous | 2 | 2008 | 107 | 0.080 |
Why?
|
| Drug Synergism | 4 | 2018 | 1364 | 0.080 |
Why?
|
| Intestinal Absorption | 1 | 2009 | 223 | 0.080 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2008 | 40 | 0.080 |
Why?
|
| Cell Differentiation | 3 | 2015 | 4195 | 0.080 |
Why?
|
| Drug Design | 2 | 2007 | 378 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2010 | 451 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2008 | 27 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 227 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 1140 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 2009 | 237 | 0.080 |
Why?
|
| Glucosides | 1 | 2008 | 63 | 0.080 |
Why?
|
| K562 Cells | 4 | 2013 | 345 | 0.080 |
Why?
|
| Medication Adherence | 2 | 2012 | 519 | 0.080 |
Why?
|
| Immunologic Factors | 2 | 2010 | 669 | 0.080 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 72 | 0.080 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 371 | 0.080 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2008 | 42 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 7827 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 33 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2008 | 163 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2008 | 112 | 0.070 |
Why?
|
| Medicare | 1 | 2013 | 934 | 0.070 |
Why?
|
| Vaccination | 2 | 2024 | 1156 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2014 | 1552 | 0.070 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 63 | 0.070 |
Why?
|
| Alleles | 4 | 2019 | 2599 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2008 | 98 | 0.070 |
Why?
|
| Models, Chemical | 2 | 2005 | 180 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 3947 | 0.070 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2008 | 88 | 0.070 |
Why?
|
| Pravastatin | 1 | 2007 | 33 | 0.070 |
Why?
|
| Bone Marrow Diseases | 2 | 2006 | 187 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2009 | 249 | 0.070 |
Why?
|
| Cognition | 1 | 2013 | 982 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8602 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2015 | 3026 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 356 | 0.070 |
Why?
|
| Abnormal Karyotype | 2 | 2019 | 101 | 0.070 |
Why?
|
| Fungemia | 2 | 2006 | 119 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 2 | 2002 | 429 | 0.070 |
Why?
|
| Nucleosides | 1 | 2007 | 63 | 0.070 |
Why?
|
| Injections, Intravenous | 4 | 2011 | 596 | 0.070 |
Why?
|
| Genes, src | 1 | 2006 | 28 | 0.070 |
Why?
|
| Extracellular Fluid | 1 | 2006 | 19 | 0.070 |
Why?
|
| Acute Kidney Injury | 2 | 2015 | 784 | 0.070 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2008 | 129 | 0.070 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 46 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 5755 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 355 | 0.070 |
Why?
|
| Heart | 1 | 2013 | 1214 | 0.070 |
Why?
|
| Farnesyl-Diphosphate Farnesyltransferase | 1 | 2006 | 2 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2007 | 84 | 0.070 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 1075 | 0.070 |
Why?
|
| Drugs, Investigational | 2 | 2007 | 129 | 0.070 |
Why?
|
| Drug Eruptions | 2 | 2013 | 271 | 0.070 |
Why?
|
| Eosinophils | 2 | 2009 | 168 | 0.070 |
Why?
|
| Neutrophils | 3 | 2012 | 876 | 0.070 |
Why?
|
| Strongyloidiasis | 1 | 2006 | 58 | 0.070 |
Why?
|
| Amifostine | 2 | 2003 | 99 | 0.070 |
Why?
|
| Area Under Curve | 3 | 2020 | 729 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2006 | 1614 | 0.070 |
Why?
|
| Computer Simulation | 2 | 2008 | 1572 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2006 | 102 | 0.060 |
Why?
|
| Cytokines | 5 | 2015 | 2841 | 0.060 |
Why?
|
| Survival | 3 | 2018 | 184 | 0.060 |
Why?
|
| Graft Rejection | 2 | 2007 | 865 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2007 | 249 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2008 | 613 | 0.060 |
Why?
|
| Sirolimus | 1 | 2010 | 833 | 0.060 |
Why?
|
| Forecasting | 1 | 2008 | 706 | 0.060 |
Why?
|
| Triazoles | 1 | 2009 | 629 | 0.060 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2005 | 45 | 0.060 |
Why?
|
| Phthalazines | 1 | 2007 | 263 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 621 | 0.060 |
Why?
|
| CD52 Antigen | 4 | 2006 | 47 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 3 | 2005 | 1772 | 0.060 |
Why?
|
| Proteins | 4 | 2000 | 2058 | 0.060 |
Why?
|
| Tissue Distribution | 3 | 2012 | 946 | 0.060 |
Why?
|
| Syndrome | 3 | 2007 | 1405 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 486 | 0.060 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2017 | 122 | 0.060 |
Why?
|
| Bilirubin | 3 | 2014 | 224 | 0.060 |
Why?
|
| DNA, Neoplasm | 4 | 2018 | 1972 | 0.060 |
Why?
|
| Lymphocyte Count | 3 | 2018 | 485 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 2576 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 809 | 0.060 |
Why?
|
| RNA | 2 | 2007 | 1072 | 0.060 |
Why?
|
| Ligands | 2 | 2018 | 1057 | 0.060 |
Why?
|
| Constipation | 2 | 2021 | 184 | 0.060 |
Why?
|
| Filgrastim | 1 | 2004 | 194 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2014 | 5788 | 0.060 |
Why?
|
| Genotype | 5 | 2013 | 4266 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 321 | 0.060 |
Why?
|
| Iron | 1 | 2007 | 382 | 0.060 |
Why?
|
| Brazil | 1 | 2024 | 172 | 0.060 |
Why?
|
| Hypopigmentation | 1 | 2003 | 27 | 0.060 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2003 | 18 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1295 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2003 | 48 | 0.060 |
Why?
|
| Life Tables | 3 | 2002 | 122 | 0.060 |
Why?
|
| Cholesterol | 1 | 2007 | 681 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 6782 | 0.060 |
Why?
|
| Stomatitis | 3 | 2016 | 193 | 0.060 |
Why?
|
| Palliative Care | 1 | 2015 | 2159 | 0.060 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 60 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 94 | 0.060 |
Why?
|
| Caspases | 4 | 2009 | 687 | 0.050 |
Why?
|
| Dioxygenases | 2 | 2015 | 171 | 0.050 |
Why?
|
| Models, Animal | 1 | 2006 | 675 | 0.050 |
Why?
|
| Chickenpox | 1 | 2003 | 34 | 0.050 |
Why?
|
| Transcriptome | 1 | 2012 | 1950 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1132 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2003 | 44 | 0.050 |
Why?
|
| U937 Cells | 2 | 2015 | 179 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2011 | 316 | 0.050 |
Why?
|
| Congenital Abnormalities | 1 | 2006 | 281 | 0.050 |
Why?
|
| Histones | 5 | 2008 | 1514 | 0.050 |
Why?
|
| Thioguanine | 2 | 2014 | 70 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2002 | 663 | 0.050 |
Why?
|
| Cholagogues and Choleretics | 1 | 2002 | 38 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 4 | 2006 | 79 | 0.050 |
Why?
|
| Radiation-Protective Agents | 1 | 2003 | 129 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2002 | 55 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2003 | 53 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4509 | 0.050 |
Why?
|
| Amino Acid Sequence | 4 | 2015 | 4635 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 1105 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 109 | 0.050 |
Why?
|
| Nitrophenols | 2 | 2013 | 95 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2019 | 1241 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2002 | 85 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 228 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 4371 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2003 | 190 | 0.050 |
Why?
|
| Drug Combinations | 4 | 2006 | 636 | 0.050 |
Why?
|
| Organ Size | 2 | 2015 | 727 | 0.050 |
Why?
|
| Prevalence | 3 | 2015 | 3426 | 0.050 |
Why?
|
| Half-Life | 2 | 2015 | 269 | 0.050 |
Why?
|
| Pharmacokinetics | 3 | 2008 | 40 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 271 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 159 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 232 | 0.050 |
Why?
|
| Catalytic Domain | 2 | 2014 | 306 | 0.050 |
Why?
|
| Acetylation | 3 | 2007 | 517 | 0.050 |
Why?
|
| Research | 1 | 2004 | 431 | 0.050 |
Why?
|
| Japan | 1 | 2022 | 237 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2013 | 242 | 0.050 |
Why?
|
| Alkaloids | 1 | 2001 | 84 | 0.050 |
Why?
|
| Radioimmunoassay | 4 | 2002 | 209 | 0.050 |
Why?
|
| International Agencies | 2 | 2012 | 108 | 0.050 |
Why?
|
| Indoles | 2 | 2006 | 1034 | 0.050 |
Why?
|
| Phosphatidylglycerols | 1 | 2001 | 32 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2007 | 4200 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 357 | 0.050 |
Why?
|
| Hyperbilirubinemia | 2 | 2016 | 79 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2015 | 286 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5330 | 0.050 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2013 | 50 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2021 | 186 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 303 | 0.050 |
Why?
|
| Epoxy Compounds | 2 | 2011 | 57 | 0.050 |
Why?
|
| Sesquiterpenes | 1 | 2001 | 72 | 0.050 |
Why?
|
| Arthralgia | 1 | 2021 | 97 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3980 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2001 | 129 | 0.050 |
Why?
|
| Sepsis | 2 | 2003 | 689 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2001 | 190 | 0.050 |
Why?
|
| Benzylamines | 1 | 2020 | 101 | 0.050 |
Why?
|
| Pancytopenia | 2 | 2016 | 119 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 668 | 0.040 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2019 | 12 | 0.040 |
Why?
|
| Societies | 1 | 2010 | 38 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1999 | 507 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 156 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 460 | 0.040 |
Why?
|
| Genetic Markers | 4 | 2010 | 1077 | 0.040 |
Why?
|
| Transplantation, Autologous | 3 | 2013 | 2048 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2020 | 119 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2001 | 591 | 0.040 |
Why?
|
| Histocompatibility Testing | 2 | 2013 | 484 | 0.040 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2000 | 34 | 0.040 |
Why?
|
| Bayes Theorem | 3 | 2014 | 1055 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 1999 | 84 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2003 | 366 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 3 | 2004 | 241 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 2 | 2014 | 148 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4639 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 2000 | 102 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2015 | 2619 | 0.040 |
Why?
|
| Protein Array Analysis | 2 | 2012 | 505 | 0.040 |
Why?
|
| Blotting, Southern | 4 | 2000 | 455 | 0.040 |
Why?
|
| Protein Transport | 2 | 2014 | 739 | 0.040 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2015 | 79 | 0.040 |
Why?
|
| Skin Ulcer | 1 | 1999 | 72 | 0.040 |
Why?
|
| Drugs, Generic | 1 | 2019 | 35 | 0.040 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 48 | 0.040 |
Why?
|
| Alanine Transaminase | 2 | 2014 | 240 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 1086 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2000 | 183 | 0.040 |
Why?
|
| Hematology | 1 | 2010 | 99 | 0.040 |
Why?
|
| Pseudotumor Cerebri | 1 | 1999 | 62 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 84 | 0.040 |
Why?
|
| Cell Line | 4 | 2008 | 5433 | 0.040 |
Why?
|
| Mitochondria | 3 | 2013 | 1314 | 0.040 |
Why?
|
| Stem Cells | 2 | 2020 | 1236 | 0.040 |
Why?
|
| Quinazolines | 1 | 2003 | 953 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2000 | 419 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 324 | 0.040 |
Why?
|
| RNA Interference | 2 | 2014 | 1397 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2007 | 1832 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 101 | 0.040 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2011 | 289 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 1660 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2019 | 251 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1116 | 0.040 |
Why?
|
| Carrier Proteins | 3 | 2003 | 2139 | 0.040 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 2 | 2008 | 53 | 0.040 |
Why?
|
| RNA Splicing Factors | 1 | 2018 | 154 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 718 | 0.040 |
Why?
|
| Immunoblotting | 3 | 2008 | 909 | 0.040 |
Why?
|
| Hepatomegaly | 2 | 2010 | 72 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 622 | 0.040 |
Why?
|
| Proto-Oncogenes | 2 | 2008 | 208 | 0.040 |
Why?
|
| Receptor, EphA3 | 1 | 2016 | 2 | 0.040 |
Why?
|
| beta Catenin | 2 | 2013 | 691 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1566 | 0.030 |
Why?
|
| Immunoprecipitation | 2 | 2008 | 593 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1997 | 138 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2010 | 2913 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 550 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 344 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2496 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2007 | 532 | 0.030 |
Why?
|
| beta-Thromboglobulin | 1 | 1995 | 5 | 0.030 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2008 | 215 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 3262 | 0.030 |
Why?
|
| Protein Prenylation | 2 | 2007 | 21 | 0.030 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 1995 | 16 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2000 | 1180 | 0.030 |
Why?
|
| Histone Deacetylases | 2 | 2008 | 366 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 2011 | 915 | 0.030 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 276 | 0.030 |
Why?
|
| Tumor Suppressor Protein p14ARF | 3 | 2000 | 101 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 1995 | 37 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1996 | 101 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2013 | 374 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 189 | 0.030 |
Why?
|
| Platelet Activation | 1 | 1995 | 100 | 0.030 |
Why?
|
| Myelin Basic Protein | 1 | 2015 | 96 | 0.030 |
Why?
|
| Esophagitis | 1 | 2016 | 210 | 0.030 |
Why?
|
| Fibrinogen | 1 | 1996 | 214 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1994 | 55 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 940 | 0.030 |
Why?
|
| Busulfan | 2 | 2013 | 786 | 0.030 |
Why?
|
| Muscle Cramp | 1 | 2014 | 7 | 0.030 |
Why?
|
| Dizziness | 1 | 2014 | 43 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 277 | 0.030 |
Why?
|
| Myalgia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Protein Isoforms | 2 | 2007 | 860 | 0.030 |
Why?
|
| Transaminases | 1 | 2014 | 82 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 7929 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 531 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2009 | 620 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 995 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 289 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 2013 | 68 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1995 | 177 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 98 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 1534 | 0.030 |
Why?
|
| Endoglin | 1 | 2013 | 41 | 0.030 |
Why?
|
| Enzyme Activators | 1 | 2013 | 21 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 140 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2013 | 44 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2013 | 24 | 0.030 |
Why?
|
| Liver | 2 | 2019 | 3124 | 0.030 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2014 | 107 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 59 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 233 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 1327 | 0.030 |
Why?
|
| HLA-DRB1 Chains | 1 | 2013 | 89 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2013 | 105 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 351 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 227 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1606 | 0.030 |
Why?
|
| Mouth Mucosa | 2 | 2004 | 225 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 273 | 0.030 |
Why?
|
| Chills | 2 | 2003 | 12 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 150 | 0.030 |
Why?
|
| Infusions, Parenteral | 2 | 2003 | 197 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 370 | 0.030 |
Why?
|
| Patient Care | 1 | 2013 | 151 | 0.030 |
Why?
|
| Terminally Ill | 1 | 2013 | 96 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2009 | 2106 | 0.030 |
Why?
|
| Enediynes | 1 | 2012 | 13 | 0.030 |
Why?
|
| Base Sequence | 3 | 2008 | 5500 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 42 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 207 | 0.030 |
Why?
|
| Therapeutic Equivalency | 2 | 2002 | 49 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2006 | 320 | 0.020 |
Why?
|
| Allografts | 1 | 2014 | 684 | 0.020 |
Why?
|
| WT1 Proteins | 1 | 2012 | 108 | 0.020 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2011 | 5 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2011 | 103 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1209 | 0.020 |
Why?
|
| Pain | 2 | 2014 | 1696 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 689 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 136 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2011 | 69 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 898 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1074 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2006 | 815 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1020 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1146 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2014 | 1718 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3671 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 246 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 445 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 1100 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 4071 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 655 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 967 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 162 | 0.020 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2010 | 26 | 0.020 |
Why?
|
| Peptide Library | 1 | 2010 | 165 | 0.020 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2010 | 33 | 0.020 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2010 | 56 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 790 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2001 | 380 | 0.020 |
Why?
|
| Hemorrhage | 2 | 2010 | 747 | 0.020 |
Why?
|
| Cell Division | 2 | 2008 | 2711 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 317 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2010 | 116 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 64 | 0.020 |
Why?
|
| DNA Primers | 2 | 2007 | 1513 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 2009 | 38 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2014 | 812 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2002 | 758 | 0.020 |
Why?
|
| Radiography | 2 | 2007 | 1993 | 0.020 |
Why?
|
| Trypsin | 1 | 2009 | 158 | 0.020 |
Why?
|
| Genes, myc | 1 | 2011 | 375 | 0.020 |
Why?
|
| Voriconazole | 1 | 2009 | 115 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 674 | 0.020 |
Why?
|
| Ascites | 1 | 2010 | 216 | 0.020 |
Why?
|
| Dyspnea | 2 | 2003 | 421 | 0.020 |
Why?
|
| Health | 1 | 2009 | 51 | 0.020 |
Why?
|
| Sarcoma | 1 | 2000 | 1842 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2029 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 155 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 782 | 0.020 |
Why?
|
| Australia | 1 | 2009 | 261 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2009 | 64 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 237 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2008 | 163 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 183 | 0.020 |
Why?
|
| Crystallography | 1 | 2008 | 57 | 0.020 |
Why?
|
| Isoleucine | 1 | 2008 | 33 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 1095 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 1388 | 0.020 |
Why?
|
| Static Electricity | 1 | 2008 | 62 | 0.020 |
Why?
|
| Receptors, Erythropoietin | 1 | 2008 | 76 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2009 | 168 | 0.020 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2008 | 70 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2008 | 128 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2219 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1742 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 453 | 0.020 |
Why?
|
| Threonine | 1 | 2008 | 165 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 190 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 267 | 0.020 |
Why?
|
| Methionine | 1 | 2008 | 170 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2008 | 341 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2008 | 177 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 1077 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 438 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2015 | 1730 | 0.020 |
Why?
|
| Ferritins | 1 | 2007 | 155 | 0.020 |
Why?
|
| Homeostasis | 1 | 2012 | 959 | 0.020 |
Why?
|
| Cell Shape | 1 | 2007 | 130 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2008 | 131 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2009 | 331 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 214 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2008 | 1093 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 771 | 0.020 |
Why?
|
| Thiabendazole | 1 | 2006 | 11 | 0.020 |
Why?
|
| Ivermectin | 1 | 2006 | 18 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 1720 | 0.020 |
Why?
|
| Cinnamates | 1 | 2006 | 34 | 0.020 |
Why?
|
| Anemia, Myelophthisic | 1 | 2006 | 5 | 0.020 |
Why?
|
| Granulocytes | 1 | 2007 | 243 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 253 | 0.020 |
Why?
|
| Donor Selection | 1 | 2007 | 106 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 703 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 2504 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2006 | 117 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2006 | 70 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2006 | 96 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2298 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2006 | 28 | 0.020 |
Why?
|
| DNA | 2 | 2005 | 3089 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 326 | 0.020 |
Why?
|
| Craniofacial Abnormalities | 1 | 2008 | 249 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2008 | 335 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 641 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2007 | 224 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 7791 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 593 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 57 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2006 | 188 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2008 | 392 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 54 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 82 | 0.020 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 473 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 72 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 109 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 102 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2006 | 117 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 770 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 124 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 170 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1707 | 0.020 |
Why?
|
| Tubulin | 1 | 2005 | 203 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 192 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 169 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2006 | 452 | 0.020 |
Why?
|
| Echinocandins | 1 | 2006 | 134 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 89 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2006 | 204 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2008 | 392 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2008 | 507 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 304 | 0.010 |
Why?
|
| ROC Curve | 1 | 2008 | 1248 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 360 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 5841 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2005 | 253 | 0.010 |
Why?
|
| CD13 Antigens | 1 | 2004 | 43 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 330 | 0.010 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2003 | 29 | 0.010 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2003 | 22 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2007 | 1278 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 169 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1133 | 0.010 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2003 | 32 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 2007 | 3080 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2004 | 246 | 0.010 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2003 | 58 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 138 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 1999 | 1650 | 0.010 |
Why?
|
| Registries | 1 | 2011 | 2252 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 7237 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2003 | 52 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1559 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 195 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 177 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2003 | 106 | 0.010 |
Why?
|
| Genome, Human | 1 | 2011 | 1885 | 0.010 |
Why?
|
| Infarction | 1 | 2002 | 35 | 0.010 |
Why?
|
| Folic Acid Antagonists | 1 | 2002 | 48 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2008 | 1740 | 0.010 |
Why?
|
| Consciousness Disorders | 1 | 2002 | 27 | 0.010 |
Why?
|
| Receptors, TIE | 1 | 2002 | 6 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 2002 | 51 | 0.010 |
Why?
|
| Indomethacin | 1 | 2002 | 115 | 0.010 |
Why?
|
| Skin | 1 | 2008 | 1284 | 0.010 |
Why?
|
| Receptor, TIE-1 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7476 | 0.010 |
Why?
|
| Graft Survival | 1 | 2006 | 1092 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2003 | 126 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 265 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 243 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 131 | 0.010 |
Why?
|
| Methylation | 1 | 2003 | 626 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2002 | 161 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 1259 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 1015 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 339 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2001 | 87 | 0.010 |
Why?
|
| Hypotension | 1 | 2003 | 237 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1999 | 5248 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2002 | 406 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 249 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 384 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 1155 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2006 | 514 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2005 | 919 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 170 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 955 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 207 | 0.010 |
Why?
|
| Prednisolone | 1 | 2001 | 133 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2001 | 85 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2001 | 154 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 834 | 0.010 |
Why?
|
| Calibration | 1 | 2001 | 346 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 1054 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2002 | 498 | 0.010 |
Why?
|
| Bacteremia | 1 | 2006 | 722 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 369 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 364 | 0.010 |
Why?
|
| Paranoid Disorders | 1 | 1999 | 9 | 0.010 |
Why?
|
| Femur Head Necrosis | 1 | 1999 | 11 | 0.010 |
Why?
|
| Enzymes, Immobilized | 1 | 1999 | 12 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 2000 | 90 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2000 | 318 | 0.010 |
Why?
|
| Syncope | 1 | 1999 | 61 | 0.010 |
Why?
|
| Colloids | 1 | 1999 | 36 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 1041 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 1999 | 81 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 1048 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 852 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2198 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 611 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 485 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 721 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 195 | 0.010 |
Why?
|
| Ataxia | 1 | 1999 | 183 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 1659 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 1912 | 0.010 |
Why?
|
| DNA Damage | 1 | 2005 | 1989 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2000 | 529 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1997 | 159 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2004 | 1255 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 1569 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1999 | 1588 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2003 | 752 | 0.010 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 1995 | 18 | 0.010 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1995 | 95 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 2497 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1995 | 224 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 1995 | 280 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 1458 | 0.010 |
Why?
|
| Neurons | 1 | 2002 | 2461 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 16242 | 0.000 |
Why?
|